bioMérieux, a major player in the field of in vitro diagnostics, is reinforcing its commitment to combating cardiovascular diseases by launching VIDAS Troponin I Ultra, a first-line parameter in acute coronary syndrome diagnostics.
bioMérieux will be awarded up to €54.5 million by France’s Agence de l’Innovation Industrielle to pursue molecular biology research
bioMérieux today announced that it will be awarded up to €54.5 million over the next ten years by France’s Agence de l’Innovation Industrielle to help fund the “Advanced Diagnostics and New therapeutic Approaches” (ADNA) program, led by Mérieux Alliance. Of this amount, €25.6 million will be in the form of grants and €28.9 million in the form of loans. The financing is subject to approval by the European Union, which is expected to make a decision in the second quarter of 2007.
bioMérieux was proud to present its ninth Award on Pathogen Research at the “Eleventh Conference on Food Microbiology”, held this year by the University of Ghent, Belgium, on September 14th and 15th.
A major player in in vitro diagnostics specialized in the fight against infectious diseases, bioMérieux confirms its success in the fight against the AIDS virus in Africa.
bioMérieux, a global leader in the field of in vitro diagnostics, today announced the closing of the sale of its hemostasis range of products to Trinity Biotech plc.
bioMérieux, the world's third-largest diagnostic company in the field of infectious diseases, has won a new contract ; the company will be the exclusive provider of equipment for measuring HIV viral load in the Democratic Republic of Congo.
bioMérieux NucliSENS® easyMAG™ Receives Technology Innovation of the Year Award from Frost & Sullivan
2006 Technology Innovation Award of the Year in the field of In Vitro Diagnostics. bioMérieux has been the proud recipient of 2006 Technology Innovation of the Year award in the field of in vitro diagnostics. After extensive evaluation, Frost & Sullivan, an industry-leading global growth consulting company, chose bioMérieux for their development of the NucliSENS easyMAG system. The NucliSENS easyMAG is a breakthrough platform based on the company’s proprietary technologies and features premium nucleic acid extraction quality and enhanced productivity through highly accessible instrumentation.
ExonHit and bioMérieux reach an important research milestone in the molecular detection of breast cancer from blood samples
ExonHit Therapeutics, a French drug and diagnostic discovery company, and bioMérieux, a major player in the field of in vitro diagnostics, announce today that they have reached an important research milestone in the diagnosis of breast cancer.
As a major player in the field of in vitro diagnostics, bioMérieux confirms its commitment to the fight against emerging diseases and launches its avian flu detection test.
bioMérieux annonce la parution d’un ouvrage consacré aux Infections Liées aux Soins (ILS). Ce livre a été élaboré par les professeurs Marie-Laure Joly-Guillou et Bernard Régnier. Le Docteur Jean Carlet en a signé la préface.